Articles tagged with Cancer
A genomic study found two previously unreported truncating germline variants in BRCA2, suggesting inherited alterations may contribute to susceptibility to multiple primary lung cancers. The study also points toward important clinical applications, including the use of PARP inhibitors and molecularly targeted approaches for treatment.
A new AI model, SpliceSelectNet, accurately predicts RNA splicing by capturing long-range DNA signals. The model's hierarchical Transformer architecture preserves high computational efficiency while maintaining single-nucleotide resolution, enabling accurate analysis of genomic regions.
A CU Anschutz study reveals reduced mitochondrial efficiency in healthy yet sedentary individuals, which may precede the development of major diseases like cancer, diabetes, and Alzheimer's. Regular exercise acts as a literal shield for cellular health, helping mitochondria seamlessly switch between burning fat and carbohydrates.
Recent research suggests that senescence often limits stem cell activity in normal tissues but can also promote tumor progression in cancer. Understanding the dynamic interplay between these two biological processes is crucial for developing safer regenerative therapies and more effective cancer treatments.
Researchers at the University of Turku have developed a reliable laboratory model to study BAP1-deficient melanomas, which are resistant to immunotherapies. The new tool could lead to novel immunotherapy combinations for aggressive melanomas.
Researchers at Texas A&M University develop a laser technique called TRIP to directly measure quantum forces shaping proteins, enabling accurate prediction of how pharmaceutical drugs interact with them. This breakthrough could lead to the design of medicines tailored to specific diseases, revolutionizing precision medicine.
Researchers identified miR-29a as a pivotal regulator of cancer development, which can act as both a tumor suppressor and an oncogene. Natural bioactive compounds such as curcumin, EGCG, and resveratrol have been shown to restore normal miR-29a expression through epigenetic remodeling and inhibition of oncogenic signaling pathways.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center receive $1.7M grant to advance CAR T-cell therapies for metastatic castration-resistant prostate cancer. They will investigate a new approach combining engineered nanovial technology with single-cell analysis to rapidly evaluate and optimize dual-targeted CAR T-cell therapies.
Researchers discover a novel mechanism where PVT1 and EIF4A1 drive gastric cancer metastasis through the Notch-1 signaling pathway, resulting in increased tumour cell migration, invasion, and proliferation. Elevated STC1 levels confirm its role as a key downstream effector of this axis.
Researchers developed an AI framework to identify viable target antigens for CAR T cell therapy, using publicly available single-cell RNA sequencing data. The framework showed robust tumor-killing activity in mouse models of multiple cancer types, including melanoma, leukemia, and colorectal cancer.
Researchers have uncovered a potential strategy to eliminate cancer cells that survive KRAS inhibition, preventing relapse. By targeting the metabolic pathways that support the survival of drug-tolerant persister cells, treatment regimens could be designed to shrink tumors and prevent cancer recurrence.
Combined hepatocellular-cholangiocarcinoma is a rare and aggressive form of primary liver cancer that poses significant diagnostic and therapeutic challenges. The absence of standardized treatment guidelines limits effective management, emphasizing the need for thorough pathological evaluation and multidisciplinary management.
Researchers found frequent silencing of TRAIL-R2 in breast tumors through promoter hypermethylation, associated with invasive ductal carcinoma and advanced tumor stage. Lower TRAIL-R2 expression was linked to more aggressive disease and reduced overall survival.
Researchers discover microbes can induce immunogenic cell death, activating immune system against tumors. This process transforms immunologically 'cold,' therapy-resistant tumors into 'hot,' responsive ones by triggering damage-associated molecular patterns (DAMPs).
A phase III trial is investigating whether an immune-boosting drug can help keep early-stage lung cancer from coming back after surgery. Researchers aim to enroll 336 participants with stage I non-small cell lung cancer and determine if the treatment reduces recurrence.
Access to fertility preservation (FP) care is restricted among female adolescents and young adults with cancer due to costly and invasive interventions. The review highlights disparities in FP delivery and access based on age, socioeconomic status, and cancer type.
Researchers developed a method combining AI and mathematical models to accelerate MRI scans for breast cancer imaging, achieving improved tumor visibility and high diagnostic sensitivity. The ELITE method has the potential to improve not only MRI scans but also other imaging platforms.
Researchers developed RNovA algorithm to identify new PTMs in human cells, expanding capabilities of machine learning in basic biological research. The discovery aims to advance diagnostics and broaden biologists' horizons for cancer and other diseases.
A new blood test, Stockholm3, detected significantly more aggressive prostate cancers than the PSA test without increasing unnecessary follow-ups. The study shows that Stockholm3 identifies 90% of aggressive cancer cases, compared to 74% for PSA.
A new study from Kaiser Permanente found that combining AI mammographic risk scores with polygenic and clinical risk scores more accurately identifies women at high risk of developing breast cancer than clinical risk scores used alone. The combined model was found to improve prediction accuracy, particularly among women at highest risk.
The collaboration aims to eliminate barriers to screening and access for medically underserved women, leveraging data science and community-based research to develop targeted solutions. By listening to residents' experiences and challenges, USC and Novartis will create lasting improvements in breast cancer care.
Researchers seek to understand the biological mechanisms behind Ewing sarcoma's rapid growth and spread, developing new tools to visualize DNA structures and regulate gene expression. This could lead to personalized cancer treatments targeting specific molecules for improved patient outcomes.
Researchers have developed a versatile uncertainty-aware AI framework called TRUECAM that provides customizable accuracy guarantees for cancer subtype classifications. TRUECAM outperforms existing approaches to digital pathology AI uncertainty quantification, detecting out-of-scope inputs and improving fairness across sex and race.
A target trial emulation study found that delaying treatment of moderate pre-cancerous cervical cells (CIN 2) does not increase three-year cancer risk and reduces unnecessary excisions. The study suggests it may be safe to delay treatment, especially for lower-risk CIN 2, by adopting careful follow-up strategies.
Researchers found that patients often wait an average of four weeks for biomarker test results, with the first step taking up to 23 days to order testing. This delay can lead to mismatched therapies, toxic side effects, and reduced treatment options, emphasizing the need for improved testing turnaround times.
Researchers developed biohybrid magnetic microbots from natural microalgae to overcome drug penetration limitations in bladder cancer treatment. The technology increased drug delivery by over ten times compared to standard treatment methods, reducing tumour burden and improving treatment effectiveness.
Researchers develop cellular model to reproduce NF1-associated tumour progression, identifying new therapeutic opportunities. The combination of olaparib and selumetinib shows promise in reducing tumour growth.
A study found that younger generations are aging faster biologically, increasing their risk of early-onset cancers. The study linked accelerated aging in immune systems and fat tissue to higher risks of lung and colorectal cancer.
Dr. Nowicki's research aims to develop a next-generation CAR-T cell therapy targeting GD2, a protein found on osteosarcoma cells, with enhanced immune-signaling molecule TNF-alpha. The grant will support preclinical studies to evaluate safety and effectiveness in laboratory and animal models.
Researchers at Salk Institute uncover an unexpected role for HDAC enzymes in controlling critical genes involved in DNA repair, making pancreatic cells more vulnerable to therapies that induce DNA damage. This finding paves the way for new treatment strategies combining entinostat with DNA-damaging therapies.
Researchers develop AI framework using principles of superposition and entanglement to tailor cancer treatment to patients' entire molecular background. The technique predicts health outcomes and suggests genes to target, outperforming standard biomarkers in clinical trials.
Researchers have developed a polymer-based microring resonator array with over 40 elements, demonstrating broadband acoustic detection and fine spatial resolution. The system achieved strong correspondence with biological structures, including blood vessel regions, in imaging mouse prostate tissue.
The article explores ways clinicians can deliver care tailored to each patient's unique needs, priorities, and identities. Research highlights the importance of considering life transitions in supporting adolescents and young adults with cancer.
Researchers developed an AI-powered platform to track drug responses across thousands of patient-derived organoids, enabling real-time monitoring and analysis of tumor heterogeneity. The platform successfully measured how tumor organoids responded to drug treatment, providing a detailed view of treatment responses at the level of indiv...
A research team from the University of Liège uncovered a previously unrecognized mechanism that promotes cancer cell survival under therapeutic pressure. Cancer cells reprogram their lipid metabolism to sustain proliferation, with key enzyme SCD1 cooperating with epigenetic regulator HDAC2 to support tumor growth.
Researchers at the University of Texas MD Anderson Cancer Center discovered a new approach to help overcome immunotherapy resistance. Copper-induced cell death, known as cuproptosis, activates the immune system and can be combined with anti-PD-L1 immunotherapy to slow tumor growth.
A large-scale study found dozens of genetic mutations linked to cancer type and ancestry, improving survival predictions in breast and glioma cancers. Combining ancestry data with tumour analyses enhances prediction accuracy, particularly for pancreatic cancer patients.
Researchers at UCSF built a robotic system to treat thousands of mini tumors, identifying shared features among persister cells that could help explain why cancer comes back. Nine drugs consistently weakened persister cells, suggesting common vulnerabilities.
Two new UH CPRIT grants will accelerate lung cancer prevention, diagnosis, and treatment. Researchers aim to develop new mRNA-based immunotherapies and a next-generation blood test for precise lung cancer detection.
Researchers from Kyushu University discovered that the circadian clock protein BMAL1 drives macrophages towards a pro-inflammatory M1 state by activating inflammatory signaling pathways. This mechanism links the body clock to intracellular metabolism and immune function, offering new insights into treating inflammatory diseases.
Johanna Joyce, a leading tumor immunologist, has begun her two-year term as President of the European Association for Cancer Research. She will focus on strategic oversight, promoting broad scientific collaboration, dialogue, and training, while addressing issues such as gender disparities in science.
A new national analysis found that mesothelioma deaths and diagnoses continue to rise in the US, with little improvement in survival rates. The disease disproportionately affects women and several high-risk states tied to shipbuilding, mining, and legacy asbestos exposure.
Researchers developed a nanowire device that selectively captures cancer-related extracellular vesicles from the blood serum of ovarian cancer patients. The technology uses high-performance zinc oxide nanowires and achieves efficient capture of cancer biomarkers with minimal physical burden on patients.
Researchers at UCLA Jonsson Comprehensive Cancer Center have been awarded a $3.2 million NIH grant to develop advanced imaging and surgical strategies for improving glioblastoma outcomes. The team aims to use pH-based imaging to guide precise tumor removal and explore targeted therapies that target the tumor's acid-regulating systems.
A team of researchers has discovered large droplets of proteins known as condensates near inactive chromosome regions within the cell nucleus that are a feature of some cancer cells. The newly found condensates store excess gene-activating protein TEAD1, regulating its activity and preventing toxicity to the cell.
A new study found that HPV-DeepSeek, an ultrasensitive blood test, can identify patients with HPV-associated head and neck cancer who may benefit from additional treatments. The test detected circulating tumor DNA in 98.1% of patients at diagnosis, significantly improving detection rates compared to existing methods.
Researchers at MIT developed an ultrasound system that creates a real-time 3D representation of the object being imaged, making it easier to identify and analyze. The AR-VIU technology can be deployed in hospitals for tasks such as placing needles during biopsies, reducing training time and increasing accuracy.
A study published in JAMA Network Open found that high consumption of sugar-sweetened beverages was linked to an increased risk of liver cancer. In contrast, artificially sweetened beverage intake showed no significant association with liver cancer risk.
Researchers at UC Irvine have discovered a mechanism that combines DNA damage and inflammatory signaling in tumor cells, potentially improving cancer treatment response. The study found that a combination of PARP inhibitors and TOP1 blockers triggers an 'alarm signal' inside cancer cells, alerting the immune system to eliminate them.
Researchers developed DNA tetrahedrons with Vitamin E-derived molecules for targeted cancer treatment, enhancing cellular uptake and improving anticancer efficacy. The modification triggered oxidative stress in cancer cells, leading to programmed cell death.
A University of Ottawa-led study has discovered a hidden network driving glioblastoma's aggressive growth, highlighting a promising target for next-generation therapies. The research reveals that a protein called OSMR plays a critical role in tumor progression and supports the survival of brain tumour stem cells.
Researchers found that extreme heat impacts daily life, access to care, and treatment-related decisions among people with cancer. Participants adapted by limiting outdoor activity, but these compromises affected health, independence, and quality of life.
Current evidence links dysregulated PTM systems to cancer biomarkers and therapeutic targets, offering a dynamic view of tumor cell state. PTM-based biomarkers may improve early detection, molecular subtyping, prognosis, and prediction of therapy response.
Researchers identified a potential therapeutic lever against advanced bladder cancer, exploiting iron-dependent tumor cell death and its upstream regulatory mechanisms. The study found that JS-K can induce ferroptosis in bladder cancer cells by damaging mitochondria and disturbing iron balance.
A new study links even moderate drinking to elevated risks of chronic diseases and premature death. The research provides a much-needed benchmark with findings that one drink per day above the daily limit increases the risk of death, disability, and chronic diseases.
A machine learning model called plasmaCHORD filters out biological noise in liquid biopsy samples, enabling clinicians to better match therapies to their patients' tumors. The model has been shown to improve the ability to distinguish tumor from white blood cell mutations in approximately 83% of cases.
Researchers identify key mechanisms and molecular targets to prevent tumor progression in patients with rhabdomyosarcoma, a rare soft tissue cancer affecting young children. Two new treatment possibilities have been highlighted, targeting the IRE1α-XBP1 signaling axis and protein TAK1.
The new textbook offers a comprehensive approach to understanding cancer, highlighting the role of environmental factors and lifestyle choices in preventing the disease. The book explores the molecular basis of cancer, including epigenetic dysregulation, and discusses efficient therapies against cancer.
Researchers have developed a new method that can detect cancer with low levels of DNA in the blood, providing more detailed information about tumour composition. This could lead to better care for cancer patients, enabling closer monitoring of treatment progress and more informed decision-making.
A new study published in Genes & Cancer identifies activated beta-catenin as a key driver of aggressive pediatric osteosarcoma progression. The researchers found that cells expressing active beta-catenin exhibited enhanced invasive capacity and cancer-associated traits, suggesting a potential therapeutic target for this aggressive cancer.